使用融合蛋白MG7-scFv/SEB与肿瘤坏死因子α联合应用协同增强癌症治疗效果

Synergistic enhancement of cancer therapy using a combination of fusion protein MG7-scFv/SEB and tumor necrosis factor alpha.

作者信息

Lu Xiaoming, Cheng Chao, Wang Guobin, Shu Xiaogang, Ma Jingwei, Tong Qiang

机构信息

Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

出版信息

Protein Pept Lett. 2013 Apr;20(4):467-72.

PMID:23016583

Abstract

The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What's more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.

摘要

融合蛋白MG7-scFv/SEB在体外和体内均已显示出对胃癌的抗肿瘤活性。肿瘤坏死因子-α（TNF-α）是一种在各种模型和应用模式中发挥抗肿瘤作用的细胞因子。在本研究中，我们探讨了MG7-scFv/SEB与TNF-α在实验性胃癌中的联合作用。在我们的实验模型中，单独给予MG7-scFv/SEB和TNF-α均可有效显著抑制肿瘤生长。此外，与单一疗法相比，MG7-scFv/SEB与TNF-α协同作用，进一步降低了荷胃癌大鼠的肿瘤生长。此外，联合治疗的荷胃癌大鼠的存活率显著高于接受MG7-scFv/SEB或TNF-α治疗的大鼠。这些结果表明，MG7-scFv/SEB与TNF-α联合治疗是一种有前景的人类癌症治疗策略。